Korro Bio, Inc. (KRRO)

Market Cap	163.74M
Revenue (ttm)	2.27M
Net Income (ttm)	-83.58M
Shares Out	9.39M
EPS (ttm)	-9.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	61,476
Open	18.27
Previous Close	18.38
Day's Range	17.10 - 18.70
52-Week Range	16.78 - 98.00
Beta	n/a
Analysts	Strong Buy
Price Target	132.17 (+657.86%)
Earnings Date	Mar 18, 2025

About KRRO

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Oct 3, 2019
• Employees: 104
• Stock Exchange: NASDAQ
• Ticker Symbol: KRRO
• Website: https://www.korrobio.com

Analyst Forecast

According to 7 analysts, the average rating for KRRO stock is "Strong Buy." The 12-month stock price forecast is $132.17, which is an increase of 657.86% from the latest price.

Price Target

$132.17

(657.86% upside)

Analyst Consensus: Strong Buy